X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Norovirus Bivalent GI.1/GII.4 VLP Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Frazier Healthcare
Deal Size: $14.2 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 30, 2021
Details:
HIL-214, a virus-like particle based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in which HIL-214 was well-tolerated and showed clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Appili Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 11, 2020
Details:
Appili Therapeutics to sponsor first clinical program in the world designed to assess the use of FUJIFILM Toyama Chemical’s favipiravir for COVID-19 as prophylaxis for outbreak control.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
